Sulzer Medica, Tutogen Will Co-Develop Device/Biologic Combo Products
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica plans to work with Tutogen to develop new products in the biologics arena as part of an expanded distribution agreement to build on earlier marketing commitments
You may also be interested in...
Tutogen Seeking Buyer, Critical Mass To Grow Tutoplast Sterile Tissue Biz
Tutogen says it is looking to pair with an orthopedic spinal device company to help bolster adoption of its sterile allograft and xenograft tissue implant products
Tutogen Seeking Buyer, Critical Mass To Grow Tutoplast Sterile Tissue Biz
Tutogen says it is looking to pair with an orthopedic spinal device company to help bolster adoption of its sterile allograft and xenograft tissue implant products
Sulzer Medica Entering Peripheral Stent Market Via IntraTherapeutics
Sulzer Medica's $145 mil. purchase of privately held IntraTherapeutics provides the firm an entry into the $300 mil. peripheral stent market and complements Sulzer's heart valve and vascular graft businesses.